Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Novel targets
Solid tumor program
Annual addressable metastatic US patients
Target and engager
Discovery > Lead optimisation > IND enabling
Status
BA211
Dual-indication*
> 10,000
HLA-A2+
TC11
αCD3 TCE
BA225
Multi-indication*
> 60,000
HLA-A2+
TC25
αCD3 TCE
Multiple
> 60,000
Multi-HLA+
Undisclosed
Solid tumor program
BA211
Dual-indication*
Status
Annual addressable metastatic US patients
> 10,000
HLA-A2+
Target and engager
TC11
αCD3 TCE
Solid tumor program
BA225
Multi-indication*
Status
Annual addressable metastatic US patients
> 60,000
HLA-A2+
Target and engager
TC25
αCD3 TCE
Solid tumor program
Multiple
Status
Annual addressable metastatic US patients
> 60,000
HLA-A2+
Target and engager
Undisclosed
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
Autoimmune program
Multiple Autoimmune Indications
Multiple HLA Options
Undisclosed
Autoimmune program
Multiple Autoimmune Indications
Status
Annual addressable metastatic US patients
Multiple HLA Options
Target and engager
Undisclosed
Other targets
Solid tumor program
Annual addressable metastatic US patients
Target and engager
Discovery > Lead optimisation > IND enabling
Status
BA202
BA201
BA2401
20,000-40,000
PRAME A2
MAGE-A4/A8
PRAME A24
Solid tumor program
BA202
BA201
BA2401
Status
Annual addressable metastatic US patients
20,000-40,000
Target and engager
PRAME A2
MAGE-A4/A8
PRAME A24